WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, February 15, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND		
☐	L1	anti-CD70	12
☐	L2	L1 and conjugate	6
☐	L3	L1 and (toxin or toxoid or cytotoxin)	4
☐	L4	ki24 or Ki-24	6
☐	L5	L4 and (toxin or toxoid or cytotoxin or apoptosis)	1

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, February 15, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND	
☐	L1	cd27 and conjugate	1221
☐	L2	L1 and Cd70	561
☐	L3	@py<=2002	31333042
☐	L4	L3 and L2	123
☐	L5	L4 and (toxin or toxoid or cytotoxin or apoptosis)	123
		DB=PGPB,USPT; THES=ASSIGNEE; PLUR=YES; OP=AND	
☐	L6	20020077458 or 6433147 or 6455040 or 20020150534 or 20020106735 or 6358508	23
☐	L7	L6 and L3	6

END OF SEARCH HISTORY

```
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:26:14 ON 15 FEB 2006

FILE 'BIOSIS' ENTERED AT 16:26:14 ON 15 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:26:14 ON 15 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:26:14 ON 15 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:26:14 ON 15 FEB 2006
COPYRIGHT (C) 2006 ACS

FILE 'DISSABS' ENTERED AT 16:26:14 ON 15 FEB 2006
COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved

FILE 'PCTFULL' ENTERED AT 16:26:14 ON 15 FEB 2006
COPYRIGHT (C) 2006 Univentio

=> s cd70 or cd27L or cd27lg or ki24 or ki-24 or anti-cd70
L1         1932 CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70

=> s toxoid or toxin or cytotoxin or apoptosis or "cell death"
L2      1360872 TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"

=> s L1 and L2
L3          839 L1 AND L2

=> dup remove
ENTER L# LIST OR (END):l3
PROCESSING COMPLETED FOR L3
L4           762 DUP REMOVE L3 (77 DUPLICATES REMOVED)

=> s L4 and py<=2002
   4 FILES SEARCHED...
L5          513 L4 AND PY<=2002

=> s calicheamicin or LLE33288 or LL-E33288
L6         2709 CALICHEAMICIN OR LLE33288 OR LL-E33288

=> s L5 and L6
L7            4 L5 AND L6

=> dis L7 1-4 bib

L7      ANSWER 1 OF 4      PCTFULL   COPYRIGHT 2006 Univentio on STN
AN      2002083921 PCTFULL  ED 20021107  EW 200243
TIEN    NULEIC ACIDS AND CORRESPONDING PROTEINS USEFUL IN THE DETECTION AND
        TREATMENT OF VARIOUS CANCERS
TIFR    ACIDES NUCLEIQUES ET PROTEINES CORRESPONDANTES UTILES POUR LA DETECTION
        ET LE TRAITEMENT DE DIVERS CANCERS
IN      JAKOBOVITS, Aya, 3135 Hutton Drive, Beverly Hills, CA 90210, US;
        CHALLITA-EID, Pia, M., 15745 Morrison Street, Encino, CA 91436, US;
        FARIS, Mary, 2538 Almaden Court, Los Angeles, CA 90077, US;
        GE, Wangmao, Apt. #314, 4838 Hollow Corner Road, Culver City, CA 90230,
        US;
        HUBERT, Rene, S., 1644 No. Occidental Boulevard, Los Angeles, CA 90026,
        US;
        MORRISON, Karen, 1044 Yale Street, Santa Monica, CA 90403, US;
        MORRISON, Robert, Kendall, 1044 Yale Street, Santa Monica, CA 90403, US;
        RAITANO, Arthur, B., 10807 Cushdon Avenue, Los Angeles, CA 90064, US
PA      AGENSYS, INC., 1545 17th Street, Santa Monica, CA 90404, US [US, US]
AG      MURASHIGE, Kate, H., Morrison & Foerster LLP, Suite 500, 3811 Valley
        Centre Drive, San Diego, CA 92130-2332, US
LAF     English
LA      English
```

DT Patent
PI ***WO 2002083921 A2 20021024***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-US11654 A 20020410
PRAI US 2001-60/283,112 20010410
US 2001-60/282,739 20010410
US 2001-60/286,630 20010425

L7 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002029032 PCTFULL ED 20020627 EW 200215
TIEN WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TIFR MANIPULATION DE CELLULE ENTIERE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT PAR REPETITION
IN SHORT, Jay, M., P.O. Box 7214, Rancho Santa Fe, CA 92067-7214, US [US, US];
FU, Pengcheng, 7588 Charmant Drive #1914, San Diego, CA 92122-5079, US [AU, US];
LATTERICH, Martin, 12539 Motellano Terrace, San Diego, CA 92130, US [DE, US];
WEI, Jing, 10725 Wexford St. #6, San Diego, CA 92131, US [CN, US];
LEVIN, Michael, 7565 Tupelo Cove, San Diego, CA 92126, US [RU, US]
PA DIVERSA CORPORATION, 4955 Directors Place, San Diego, CA 92121, US [US, US], for all designates States except US;
SHORT, Jay, M., P.O. Box 7214, Rancho Santa Fe, CA 92067-7214, US [US, US], for US only;
FU, Pengcheng, 7588 Charmant Drive #1914, San Diego, CA 92122-5079, US [AU, US], for US only;
LATTERICH, Martin, 12539 Motellano Terrace, San Diego, CA 92130, US [DE, US], for US only;
WEI, Jing, 10725 Wexford St. #6, San Diego, CA 92131, US [CN, US], for US only;
LEVIN, Michael, 7565 Tupelo Cove, San Diego, CA 92126, US [RU, US], for US only
AG EINHORN, Gregory, P., Fish & Richardson P.C., 4350 La Jolla Village Drive, San Diego, CA 92122, US
LAF English
LA English
DT Patent
PI ***WO 2002029032 A2 20020411***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US31004 A 20011001
PRAI US 2000-09/677,584 20000930
US 2001-60/279,702 20010328
US 2001-PCT/US01/19367 20010614

L7 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002018620 PCTFULL ED 20020705 EW 200210
TIEN NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
TIFR NEUTROKINE-ALPHA ET VARIANT D'EPISSAGE DE NEUTROKINE-ALPHA
IN YU, Guo-Liang, 242 Gravatt Drive, Berkeley, CA 94705, US [US, US];
EBNER, Reinhard, 9906 Shelburne Terrace #316, Gaithersburg, MD 20878, US [DE, US];
NI, Jian, 17815 Fair Lady Way, Germantown, MD 20874, US [CN, US];
ROSEN, Craig, A., 22400 Rolling Hill Lane, Laytonsville, MD 20882, US [US, US];
ULLRICH, Stephen, 4713 Rams Head Court, Rockville, MD 20853, US [US, US]
PA HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue, Rockville, MD 20850,

```
        US [US, US], for all designates States except US;
        YU, Guo-Liang, 242 Gravatt Drive, Berkeley, CA 94705, US [US, US], for
        US only;
        EBNER, Reinhard, 9906 Shelburne Terrace #316, Gaithersburg, MD 20878, US
        [DE, US], for US only;
        NI, Jian, 17815 Fair Lady Way, Germantown, MD 20874, US [CN, US], for US
        only;
        ROSEN, Craig, A., 22400 Rolling Hill Lane, Laytonsville, MD 20882, US
        [US, US], for US only;
        ULLRICH, Stephen, 4713 Rams Head Court, Rockville, MD 20853, US [US,
        US], for US only
AG      HOOVER, Kenley, 9410 Key West Avenue, Rockville, MD 20850, US
LAF     English
LA      English
DT      Patent
PI        ***WO 2002018620          A2 20020307***
DS      W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
                        CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
                        JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
                        MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
                        UA UG US UZ VN YU ZA ZW
        RW (ARIPO):     GH GM KE LS MW MZ SD SL SZ TZ UG ZW
        RW (EAPO):      AM AZ BY KG KZ MD RU TJ TM
        RW (EPO):       AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
        RW (OAPI):      BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI      WO 2001-US25549       A  20010815
PRAI    US 2000-60/225,628       20000815
        US 2000-60/227,008       20000823
        US 2000-60/234,338       20000922
        US 2000-60/240,806       20001017
        US 2000-60/250,020       20001130
        US 2001-60/276,248       20010306
        US 2001-60/293,499       20010525
        US 2001-60/296,122       20010607
        US 2001-60/304,809       20010713

L7      ANSWER 4 OF 4      PCTFULL   COPYRIGHT 2006 Univentio on STN
AN      2001096551 PCTFULL  ED 20020826
TIEN    WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A
        STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TIFR    INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE
        D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT
        REPETITION
IN      SHORT, Jay, M.
PA      DIVERSA CORPORATION;
        SHORT, Jay, M.
DT      Patent
PI        ***WO 2001096551          A2 20011220***
DS      W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
                        CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
                        IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
                        MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
                        TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ
                        UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
                        FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN
                        GW ML MR NE SN TD TG
AI      WO 2001-US19367       A  20010614
PRAI    US 2000-09/594,459       20000614
        US 2000-09/677,584       20000930


=> FIL STNGUIDE
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      47.95      48.16

FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 10, 2006 (20060210/UP).

=> dis L7 1 kwic
```

YOU HAVE REQUESTED DATA FROM FILE 'PCTFULL' - CONTINUE? (Y)/N:y

L7 ANSWER 1 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
PI ***WO 2002083921 A2 20021024***

DETD . . . maytansinoids, yttriun-4 bismuth, ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethidium. bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria ***toxin*** , Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, p4enomycin, enomycin, curicin, crotin, ***calicheamicin*** , sapaonaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotope's such as At2 11, V31, V25] Y90, ReI86 .. . .

Immunol. 12:923, 1994 and Eldridge, J. H. et al., Sem. Hematol. 30:16,1993). ***Toxin*** -targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc.

. . .
or immunization of the peptides of the invention, eg. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax ***toxin*** vectors, and the like, will be apparent to those skilled in the art from the description herein.

. . .
of Figure 2 proteins are useful to systemically treat cancers that express a protein of Figure 2, either as conjugates with a ***toxin*** or therapeutic agent, or as naked antibodies capable of inhibiting cell proliferation or function.

. . .
the invention, inhibition of ligand binding or signal transduction pathways, modulation of tumor cell differentiation, alteration of tumor angiogenesis factor profiles, and/,or ***apoptosis*** .

1 1: 1 17-127). Some therapeutic approaches involve conjugation of naked antibody to a ***toxin*** or radioisotope, such as the conjugation of Y or I... to anti-CD20 antibodies (e.g., ZevalirJm, IDEC Pharmaceuticals Corp. or BexxarTm] Coulter Pharmaceuticals),. . . of the invention can be administered in conjunction with radiation, chemotherapy or hormone ablation. Also, antibodies can be conjugated to a ***toxin*** such as ***calicheamicin*** (e.g., MylotargTm, Wyeth-Ayerst, Madison, NJ, a recombinant humanized IgG4 - kappa antibody conjugated to antitumor antibiotic ***calicheamicin***) or a maytansinoid (e.g., taxane-based Tumor-Activated Prodrug, TAP, platforn-4 ImmunoGen, Cambridge, MA, also see e.g., US Patent 5,416,064).

. . .
rnAbs act include: inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of ***apoptosis*** . The mechanism(s) by which a particular mAbs of the invention exert an anti-tumor effect is evaluated using any number of in vitro assays that evaluate ***cell*** ***death*** such as ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.

. . .
vaccines of the invention are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus ***toxoid*** , polyarnino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can. . .

. . .
class 11 molecules. Examples of such amino acid bind many HLA Class II molecules include sequences from antigens such as tetanus ***toxoid*** at positions 830-843 (QYIKANSKFIGITE; SEQ ID NO.

In vivo assays that evaluate the promotion of ***apoptosis*** are useful in evaluating therapeutic compositions.

. . .

those that specifically bind epitopes of a protein of the invention exposed on the cell surface and thus are useful in targeting mAb- ***toxin*** conjugates. Immunogens for generation of such mAbs include those designed to encode. or contain an entire protein of the invention, regions. . .

The genes in Figure 2 also play a role in cell cycle modulation and ***apoptosis*** . Parental cells and cells expressing the gene of interest are compared for differences in cell cycle regulation using a well-established BrdU assay. . .

. . .

are analyzed for entry into the GI, S, and G2M phases of the cell cycle. Alternatively, the effect of stress on ***apoptosis*** is evaluated in control parental cells and cells expressing the gene of interest, including normal and tumor prostate, colon and lung. . . various chemotherapeutic agents, such as etoposide, flutamide, etc, and protein synthesis inhibitors, such as cycloheximide. Cells are stained with annexin V-FITC and ***cell*** ***death*** is measured by FACS analysis. The modulation of ***cell*** ***death*** by genes of Figure 2 play a critical role in regulating tumor progression and tumor load.

. . .

a genes set for in Figure 2, and/or its respective gene product, plays a role in cell growth, transformation, invasion or ***apoptosis*** , it is used as a target for diagnostic, prognostic, preventative and therapeutic purposes.

. . .

S-S RKRK HN 24
254 I RV VV AV F F TCFL Py 24
277 F SH LD RL L D ESAQ ***KI*** ***24***
45 L PV L Y LI I F V ASI LL 23
517
TABLE XXIII - 154P2A8 HLA-DRB1*0101 15 - mers
POS 1 2. . .

=> dis his

(FILE 'HOME' ENTERED AT 16:25:49 ON 15 FEB 2006)

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL' ENTERED AT 16:26:14 ON 15 FEB 2006
L1 1932 S CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70
L2 1360872 S TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"
L3 839 S L1 AND L2
L4 762 DUP REMOVE L3 (77 DUPLICATES REMOVED)
L5 513 S L4 AND PY<=2002
L6 2709 S CALICHEAMICIN OR LLE33288 OR LL-E33288
L7 4 S L5 AND L6

FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006

FILE 'PCTFULL' ENTERED AT 16:34:24 ON 15 FEB 2006

FILE 'STNGUIDE' ENTERED AT 16:34:50 ON 15 FEB 2006

=> s L5 and CD27
L4 CANNOT BE SEARCHED IN STNGUIDE
The L-number cannot be used because it does not contain a query.
Enter DISPLAY HISTORY to see the sequence of commands that created this L-number.

=> s L3 and CD27
0 CD70
0 CD27L
0 CD27LG
0 KI24

```
              0 KI
              6 24
              0 KI-24
                  (KI(W)24)
              0 ANTI
              0 CD70
              0 ANTI-CD70
                  (ANTI(W)CD70)
              0 TOXOID
              0 TOXIN
              0 CYTOTOXIN
              0 APOPTOSIS
             15 "CELL"
              0 "DEATH"
              0 "CELL DEATH"
                  ("CELL"(W)"DEATH")
              0 CD27
L8            0 L3 AND CD27

=> s L1
              0 CD70
              0 CD27L
              0 CD27LG
              0 KI24
              0 KI
              6 24
              0 KI-24
                  (KI(W)24)
              0 ANTI
              0 CD70
              0 ANTI-CD70
                  (ANTI(W)CD70)
L9            0 CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70

=> FIL MEDLINE BIOSIS EMBASE CAPLUS TOXCENTER CANCERLIT DISSABS PCTFULL
'CANCERLIT' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.24      50.67

FILE 'MEDLINE' ENTERED AT 16:37:02 ON 15 FEB 2006

FILE 'BIOSIS' ENTERED AT 16:37:02 ON 15 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:37:02 ON 15 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:37:02 ON 15 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:37:02 ON 15 FEB 2006
COPYRIGHT (C) 2006 ACS

FILE 'DISSABS' ENTERED AT 16:37:02 ON 15 FEB 2006
COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved

FILE 'PCTFULL' ENTERED AT 16:37:02 ON 15 FEB 2006
COPYRIGHT (C) 2006 Univentio

=> dis his

     (FILE 'HOME' ENTERED AT 16:25:49 ON 15 FEB 2006)

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:26:14 ON 15 FEB 2006
L1          1932 S CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70
L2       1360872 S TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"
```

```
L3           839 S L1 AND L2
L4           762 DUP REMOVE L3 (77 DUPLICATES REMOVED)
L5           513 S L4 AND PY<=2002
L6          2709 S CALICHEAMICIN OR LLE33288 OR LL-E33288
L7             4 S L5 AND L6

     FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006

     FILE 'PCTFULL' ENTERED AT 16:34:24 ON 15 FEB 2006

     FILE 'STNGUIDE' ENTERED AT 16:34:50 ON 15 FEB 2006
L8             0 S L3 AND CD27
L9             0 S L1

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:37:02 ON 15 FEB 2006

=> s L5 and CD27
L10          439 L5 AND CD27

=> s L5 and ki24
L11            3 L5 AND KI24

=> dis L11 1-3 bib

L11    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
AN     2002094999 PCTFULL  ED 20021210  EW 200248
TIEN   POLYNUCLEOTIDE ENCODING A NOVEL TRP CHANNEL FAMILY MEMBER, TRP-PLIK2,
       AND SPLICE VARIANTS THEREOF
TIFR   POLYNUCLEOTIDE CODANT UN NOUVEAU MEMBRE DE LA FAMILLE DES CANAUX TRP,
       TRP-PLIK2, ET VARIANT D'EPISSAGE DE CE POLYNUCLEOTIDE
IN     LEE, Ning, 926 Rhoads Drive, Belle Mead, NJ 08807, US [US, US];
       CHEN, Jian, 121 York Drive, Princeton, NJ 08540, US [CN, US];
       FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US [US, US];
       WU, Shujian, 972 Ithan Lande, Langhorne, PA 19047, US [CN, US];
       CHANG, Han, 2 Ann's Court, Princeton Junction, NJ 08550, US [US, US];
       LEE, Liana, 8 Petunia Drive Apt. 1J, North Brunswick, NJ 08902, US [US,
       US];
       BLANAR, Michael, 1325 Summerhill Drive, Malvern, PA 19355, US [CA, US];
       BOL, David, 1467 Franklin Road, Langhorne, PA 19047, US [US, US]
PA     BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Route 206 and Provinceline
       Road, Princeton, NJ 08543-4000, US [US, US], for all designates States
       except US;
       LEE, Ning, 926 Rhoads Drive, Belle Mead, NJ 08807, US [US, US], for US
       only;
       CHEN, Jian, 121 York Drive, Princeton, NJ 08540, US [CN, US], for US
       only;
       FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US [US, US],
       for US only;
       WU, Shujian, 972 Ithan Lande, Langhorne, PA 19047, US [CN, US], for US
       only;
       CHANG, Han, 2 Ann's Court, Princeton Junction, NJ 08550, US [US, US],
       for US only;
       LEE, Liana, 8 Petunia Drive Apt. 1J, North Brunswick, NJ 08902, US [US,
       US], for US only;
       BLANAR, Michael, 1325 Summerhill Drive, Malvern, PA 19355, US [CA, US],
       for US only;
       BOL, David, 1467 Franklin Road, Langhorne, PA 19047, US [US, US], for US
       only
AG     D'AMICO, Stephen, Bristol-Myers Squibb Company, P.O. Box 4000, Route 206
       and Provinceline Road, Princeton, NJ 08543-4000, US
LAF    English
LA     English
DT     Patent
PI       ***WO 2002094999         A2 20021128***
DS     W:             AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
                      CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
                      IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
                      MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
                      TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
       RW (ARIPO):    GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
       RW (EAPO):     AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):      AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
       RW (OAPI):     BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI     WO 2002-US16164      A  20020522
```

PRAI US 2001-60/292,599 20010522
      US 2002-60/362,944 20020308

L11 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002074959 PCTFULL ED 20021010 EW 200239
TIEN A NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN EXPRESSED PREDOMINATELY IN NERVOUS SYSTEM TISSUES, HLRRNS1
TIFR HLRRNS1: NOUVELLE PROTEINE HUMAINE A REPETITIONS RICHES EN LEUCINE EXPRIMEE ESSENTIELLEMENT DANS DES TISSUS DU SYSTEME NERVEUX
IN RAMANATHAN, Chandra, 41 Alison Avenue, Wallingford, CT 06492, US; FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US; MINTIER, Gabe, 318 Morrison Ave., Hightstown, NJ 08520, US
PA BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US [US, US]
AG D'AMICO, Stephen, Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US
LAF English
LA English
DT Patent
PI ***WO 2002074959 A2 20020926***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
    RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
    RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
    RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
    RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US50457 A 20011220
PRAI US 2001-60/259,479 20010103
      US 2001-60/260,616 20010109

L11 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002044210 PCTFULL ED 20020624 EW 200223
TIEN NOVEL HUMAN NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING A NOVEL HUMAN ION CHANNEL EXPRESSED IN SPINAL CORD AND BRAIN
TIFR NOUVELLES MOLECULES D'ACIDE NUCLEIQUE HUMAIN ET POLYPEPTIDES CODANT POUR UN NOUVEAU CANAL IONIQUE HUMAIN EXPRIME DANS LA MOELLE EPINIERE ET DANS LE CERVEAU
IN GAUGHAN, Glen, 30 Mansfield Drive #1503, Northford, CT 06472, US; FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US; NELSON, Thomas, 12 Azalea Court, Lawrenceville, NJ 08648, US; MINTIER, Gabe, 318 Morrison Ave., Hightstown, NJ 08520, US; RAMANATHAN, Chandra, 41 Alison AVenue, Wallingford, CT 06492, US
PA BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US [US, US]
AG D'AMICO, Stephen, Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US
LAF English
LA English
DT Patent
PI ***WO 2002044210 A2 20020606***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
    RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
    RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
    RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
    RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US45336 A 20011130
PRAI US 2000-60/250,587 20001201

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.67	62.34

FILE 'STNGUIDE' ENTERED AT 16:38:26 ON 15 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 10, 2006 (20060210/UP).

=> dis his

     (FILE 'HOME' ENTERED AT 16:25:49 ON 15 FEB 2006)

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:26:14 ON 15 FEB 2006
L1          1932 S CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70
L2       1360872 S TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"
L3           839 S L1 AND L2
L4           762 DUP REMOVE L3 (77 DUPLICATES REMOVED)
L5           513 S L4 AND PY<=2002
L6          2709 S CALICHEAMICIN OR LLE33288 OR LL-E33288
L7             4 S L5 AND L6

     FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006

     FILE 'PCTFULL' ENTERED AT 16:34:24 ON 15 FEB 2006

     FILE 'STNGUIDE' ENTERED AT 16:34:50 ON 15 FEB 2006
L8             0 S L3 AND CD27
L9             0 S L1

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:37:02 ON 15 FEB 2006
L10          439 S L5 AND CD27
L11            3 S L5 AND KI24

     FILE 'STNGUIDE' ENTERED AT 16:38:26 ON 15 FEB 2006

=> FIL MEDLINE BIOSIS EMBASE CAPLUS TOXCENTER CANCERLIT DISSABS PCTFULL
'CANCERLIT' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.12      62.46

FILE 'MEDLINE' ENTERED AT 16:39:26 ON 15 FEB 2006

FILE 'BIOSIS' ENTERED AT 16:39:26 ON 15 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:39:26 ON 15 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:39:26 ON 15 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:39:26 ON 15 FEB 2006
COPYRIGHT (C) 2006 ACS

FILE 'DISSABS' ENTERED AT 16:39:26 ON 15 FEB 2006
COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved

FILE 'PCTFULL' ENTERED AT 16:39:26 ON 15 FEB 2006
COPYRIGHT (C) 2006 Univentio

=> dis his

     (FILE 'HOME' ENTERED AT 16:25:49 ON 15 FEB 2006)

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:26:14 ON 15 FEB 2006
L1          1932 S CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70
L2       1360872 S TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"
L3           839 S L1 AND L2
```

```
L4           762 DUP REMOVE L3 (77 DUPLICATES REMOVED)
L5           513 S L4 AND PY<=2002
L6          2709 S CALICHEAMICIN OR LLE33288 OR LL-E33288
L7             4 S L5 AND L6

     FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006

     FILE 'PCTFULL' ENTERED AT 16:34:24 ON 15 FEB 2006

     FILE 'STNGUIDE' ENTERED AT 16:34:50 ON 15 FEB 2006
L8             0 S L3 AND CD27
L9             0 S L1

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:37:02 ON 15 FEB 2006
L10          439 S L5 AND CD27
L11            3 S L5 AND KI24

     FILE 'STNGUIDE' ENTERED AT 16:38:26 ON 15 FEB 2006

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:39:26 ON 15 FEB 2006

=> s L5 and CD27 and Ki24
L12            2 L5 AND CD27 AND KI24

=> dis L12 1-2 kwic

L12    ANSWER 1 OF 2      PCTFULL   COPYRIGHT 2006 Univentio on STN
PI       ***WO 2002094999          A2 20021128***

DETD  . . . 2+ plays a pivotal role in various cell functions, ranging from
      exocytosis and contraction to gene expression and cell differentiation,
      proliferation
      and   ***apoptosis***  . Human mutations in the genes involved in
      intracellular Ca 2' handling
      result in visual defects, diabetes mellitus, disorders in the skin,. .
      .
 . . .
      of a cell in multicellular organisms often requires choosing between
      life and death. This process of cell suicide, known as programmed
        ***cell***     ***death***   or
          ***apoptosis***  , occurs during a number of events in an organisms
      life cycle, such as for
      example, in development of an embryo, during. . . an immunological
      response, or in the demise of cancerous cells after drug treatment,
      among others. The
      final outcome of cell survival versus   ***apoptosis***   is dependent
      on the balance of two
      counteracting events, the onset and speed of caspase cascade activation
      (essentially a
      protease chain reaction),. . .
 . . .
      controlled by the transcriptional
      factor complex NF-kB. For example, exposure of cells to the protein
      tumor necrosis
      factor (TNF) can signal both   ***cell***     ***death***   and
      survival, an event playing a major role in
      the regulation of immunological and inflammatory responses (Ghosh, S.,
      May, M. J.,
      Kopp,. . .
 . . .
      or indirectly, treating,
      preventing, diagnosing, and/or prognosing susceptibility to the
      following, non-
      limiting, gastrointestinal infections: Salmonella infection, E.coli
      infection, E.cofi
      0157:H7 infection, Shiga   ***Toxin***  -producing E.coli infection,
      Campylobacter infection
      (e.g., Campylobacter fetus, Campylobacter upsaliensis, Campylobacter
      hyointestinalis, Campylobacter lari, Campylobacter jejuni, Campylobacter
      concisus,
      Campy lobacter mucosalis, Campylobacter sputorum, Campylobacter. . .
 . . .
      herein, transient receptor potential channel family
```

members have been implicated in modulating cell proliferation,
differentiation,
migration, activation, exocytosis, muscle contraction, gene expression,
apoptosis .

. . .

present invention, including agonists and/or fragments thereof, have
uses that
include, modulating cell proliferation, differentiation, migration,
activation,
exocytosis, muscle contraction, gene expression, ***apoptosis*** .
signalling, pheromone
sensory signaling, smooth muscle tone, pain perception, heat perception,
osmosenstivity, and mechanosensitivity.

. . .

be involved in intracellular Ca2' homeostasis
which affects various aspects of biological functions including
mechano-regulation,
pain transduction, vasorelaxation, gene expression, cell cycle and
proliferation/ ***apoptosis*** . Since TRP-PLIK2 is dominantly
expressed in bone marrow, it
may particularly play an important role in regulating cytosolic Ca 21
in. . .

. . .

MI-MI46, MI-TI45, MI-FI44, MI-NI43] MI-Q1421 MI-11419
MI-GI40, Ml-GI39, MI-H138, MIN137, MI-SI36, MI-1135, MIN134, Ml-
L133] MI-KI32, MI-Pl31, MI-LI30, MI-EI29, MI-MI28, MI-KI27, MI-WI.26,
MI-EI25, MI- ***KI24*** , MI-LI23, MI-M122, MI-LI21, MI-HI20, MI-LI19,
Ml-
L118, MI-HI17, MI-DI16, MI-LI15, MI-KII4, MI-TI13, MI-DI12, MI-Yl11,
MI-S]IO.Ml-T]09,MI-RIO8,MI-1107,M]-YI06,MI-KI05,MI-AI04,MI-H1031-
Ml-H102, Ml-T1O1, MI-11100, Ml-E99, Ml-G98, M1-1)97] Ml-Q969 Ml-F951. .

.

. . .

or indirectly, treating,
preventing, diagnosing, and/or prognosing susceptibility to the
following, non-
limiting, gastrointestinal infections: Salmonella infection, E.coli
infection, E.coli
0157:117 infection, Shiga ***Toxin*** -producing Ecoli infection,
Campylobacter infection
(e.g., Campylobacter fetus, Campylobacter upsaliensis, Campylobacter
hyointestinalis, Campylobacter lari, Campylobacter jejuni, Campylobacter
concisus,
Campylobacter mucosalis, Campylobacter sputorum, Campylobacter rectus,
Campylobacter. . .

. . .

herein, transient receptor potential channel family
members have been implicated in modulating cell proliferation,
differentiation,
migration, activation, exocytosis, muscle contraction, gene expression,
apoptosis .

. . .

present invention, including agonists and/or fragments thereof, have
uses that
include, modulating cell proliferation, differentiation, migration,
activation,
exocytosis, muscle contraction, gene expression, ***apoptosis*** .
signalling, pheromone
sensory signaling, smooth muscle tone, pain perception, heat perception,
osmosenstivity, and mechanosensitivity.

. . .

involved in intracellular Ca 2' horneostasis
which affects various aspects of biological functions including
mechano-regulation,
pain transduction, vasorelaxation, gene expression, cell cycle and
proliferation/ ***apoptosis*** . Since TRP-PLIK2 is dominantly
expressed in bone marrow,
the TRP-PLIK2b splice variant may play an important role in regulating
cytosolic
Ca 21. . .

. . .

herein, transient receptor potential channel family
members have been implicated in modulating cell proliferation,
differentiation,
migration, activation, exocytosis, muscle contraction, gene expression,

apoptosis .

. . .
present invention, including agonists and/or fragments thereof, have uses that
include, modulating cell proliferation, differentiation, migration, activation,
exocytosis, muscle contraction, gene expression, ***apoptosis*** . signalling, pheromone
sensory signaling, smooth muscle tone, pain perception, heat perception, osmosenstivity, and mechanosensitivity.

. . .
be involved in intracellular Ca]' homeostasis
which affects various aspects of biological functions including mechano-regulation,
pain transduction, vasorelaxation, gene expression, cell cycle and proliferation/ ***apoptosis*** . Since TRP-PLIK2 is dominantly expressed in bone marrow,
the TRP-PLIK2c splice variant may play an important role in regulating cytosolic
Ca 2,. . .

. . .
herein, transient receptor potential channel family
members have been implicated in modulating cell proliferation, differentiation,
migration, activation, exocytosis, muscle contraction, gene expression,
apoptosis .

. . .
present invention, including agonists and/or fragments thereof, have uses that
include, modulating cell proliferation, differentiation, migration, activation,
exocytosis, muscle contraction, gene expression, ***apoptosis*** . signalling, pheromone
sensory signaling, smooth muscle tone, pain perception, heat perception, osmosenstivity, and mechanosensitivity.

. . .
involved in intracellular Ca 2+ homeostasis
which affects various aspects of biological functions including mechano-regulation,
pain transduction, vasorelaxation, gene expression, cell cycle and proliferation/ ***apoptosis*** . Since TRP-PLIK2 is dominantly expressed in bone marrow,
the TRP-PLIK2d splice variant may play an important role in regulating cytosolic
Ca 2,. . .

. . .
anti-peptide antibody titer may be boosted by coupling the peptide
to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus
toxoid . For instance, peptides containing cysteine residues may be coupled to a carrier
using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS),. . .

Further, an antibody or fragment thereof may be conjugated to a therapeutic
moiety such as a ***cytotoxin*** , e.g., a cytostatic or cytocidal agent, a therapeutic agent or
a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A ***cytotoxin***
or cytotoxic agent includes any agent that is detrimental to cells. Examples include
paclitaxol, cytochalasin B, grarnicidin D, ethidiurn bromide, emetine, mitomycin,
etoposide,. . .

. . .
example, the drug moiety may be a protein
or polypeptide possessing a desired biological activity. Such proteins may include, for
example, a ***toxin*** such as abrin, ricin A, pseudomonas exotoxin, or diphtheria ***toxin*** ; a
protein such as tumor necrosis factor, a-interferon, B-interferon, nerve growth factor,
platelet derived growth factor, tissue plasminogen activator, an apoptotic agent,. . .

. . .
yet to be determined,
toxins, such as ricin, saporin (Mashiba H, et al., Ann. N. Y. Acad. Sci. 1999;886:233-
5), or HC ***toxin*** (Tonukari NJ, et al., Plant Cell. 2000 Feb; 12(2):237-248), for
example. Such fusions could be used to deliver the toxins to. . .
. . .
the fusion of antibodies directed against
polypeptides of the present invention, including variants and fragments thereof, to
said toxins for delivering the ***toxin*** to specific locations in a cell, to specific tissues,
and/or to specific species. Such bifunctional antibodies are known in the art,. . . in addition to the references cited therein, are hereby incorporated by
reference in their entirety herein. In this context, the term ***toxin*** may be expanded to
include any heterologous protein, a small molecule, radionucleotides, cytotoxic drugs,
liposornes, adhesion molecules, glycoproteins, ligands, cell or tissue-specific. . . antibodies,
polyclonal antibodies and genetic material. In view of the present disclosure, one
skilled in the art could determine whether any particular ***toxin*** could be used in the
compounds of the present invention. Examples of suitable toxins listed above are
exemplary only and are not. . .
. . .
protein fusions, of the present invention, or fragments
thereof may be useful in inhibiting proliferative cells or tissues through the induction
of ***apoptosis*** . Said polypeptides may act either directly, or indirectly to induce
apoptosis of proliferative cells and tissues, for example in the activation of a death-
domain receptor, such as tumor necrosis factor (TNF) receptor-], CD95 (Fas/APO- 1),
TNF-receptor-related ***apoptosis*** -mediated protein (TRAMP) and TNF-related
apoptosis -inducing ligand (TRAEL) receptor-I and -2 (See Schulze-Osthoff K, et al.,
Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said
polypeptides may induce ***apoptosis*** through other mechanisms, such as in the
activation of other proteins which will activate ***apoptosis*** , or through stimulating the
expression of said proteins, either alone or in combination with small molecule drugs
or adjuvants, such as apoptonin,. . .

Diseases at the Cellular Level
Diseases associated with increased cell survival or the inhibition of ***apoptosis***
that could be treated, prevented, and/or diagnosed by the polynucleotides or
polypeptides and/or antagonists or agonists of the invention, include cancers (such. . .

Diseases associated with increased ***apoptosis*** that could be treated, prevented,
and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or
antagonists of the invention, include AIDS; neurodegenerative. . .
myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,
hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury)
and liver cancer); ***toxin*** -induced liver disease (such as that caused by alcohol), septic
shock, cachexia and anorexia.

By ***toxin*** is meant compounds that bind and activate endogenous cytotoxic
effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of
toxins, or any molecules. . . antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic
effector system, thymidine kinase, endonuclease, RNAse, alpha ***toxin*** , ricin, abrin,
Pseudomonas exotoxin A, diphtheria ***toxin*** , saporin, momordin, gelonin, pokeweed
antiviral protein, alpha-sarcin and cholera ***toxin*** . By cytotoxic prodrug is meant a
non-toxic compound that is converted by an enzyme, normally present in the cell, into
a cytotoxic. . .

. . .

ID# Sequence
16520 CCUUGACAGUCUCCCACACUGACAG (SEQ ID NO:310)
The TRP-PLIK2 polypeptide has been shown to be involved in the regulation
of mammalian NF-KB and ***apoptosis*** pathways. Subjecting cells with an effective
amount of the above antisense oligonucleotide resulted in a significant increase in
IkBa expression/activity providing convincing. . .

. . .

desired 5' end
using a primer specific to the ligated RNA oligonucleotide and a primer specific to the
known sequence of the ***apoptosis*** related of interest. The resultant product is then
sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant
apoptosis related.

. . .

are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also
known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta),
OPGL, FasL, ***CD27L*** . CD30L, CD40L. 4-IBBL, DcR3, OX40L, TNF-gamma
(International Publication No. WO 96/14328), AIN4-1 (International Publication No. CD 1 54, ***CD70*** , and CD 1 53.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-
superfamily. Within this family CD40, ***CD27*** , and CD30 along with their respective
ligands CD154, ***CD70*** , and CD153 have been found to regulate a variety of immune
responses. Assays which allow for the detection and/or observation of. . .

. . .

peripheral blood monocytes progressively
lose viability when cultured in absence of serum or other stimuli. Their death results
from internally regulated process (***apoptosis***). Addition to the culture of activating
factors, such as TNF-alpha dramatically improves cell survival and prevents DNA
fragmentation. Propidium iodide (PI) staining is used to measure ***apoptosis*** as follows.

CLMEN. . . renal failure,
proliferative disorders, cancers, ischemia-reperfusion injury, heart failure, immuno compromised conditions, HIV infection, disorders associated with aberrant NFkB regulation, disorders associated with aberrant ***apoptosis*** regulation, disorders in which decreasing NFkB
activity would be therapeutically desirable, disorders in which increasing NFkB activity would be therapeutically desirable, disorders in. . .

L12 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
PI ***WO 2002074959 A2 20020926***

DETD . . . described in both plants
and animals that are involved in pathogen perception, MHC class II trans-activation ,
inflammation and the regulation of ***apoptosis*** (Inohara, N., Nunez, G, ***Cell*** , ***Death*** ,
Differ., 6(9):823-4, (1999); Inohara, N., Koseki, T., -del, Pe-so, L., Hu, Y.,,Yee, C.,
Chen, S., Carrio, R.,Merino, J., Liu, D., Ni, J., Nunez, G, J. Biol, Chem. 21.,
274(21):14560-7, (1999); Inohara, N., Nunez, G, ***Cell*** ,
Death , Differ., 7(5):509-10,
(2000); Harton, JA., Ting, JP, Mol, Cell, Biol., 20(17):6185-94, (2000); Dixon, J.,
Brakebusch, C., Fassler, R., Dixon, MJ. Hum, Mol,. . .

102(a)

Such LRRs, being extracellular, are capable of directing protein-protein interactions with other receptors involved in ***apoptosis*** , inflammation and immune
responses. LLR containing proteins may also bind other extracellular ligands derived
from infectious agents and participate in the triggering and or modulating immune
responses, particularly ***apoptosis*** .

The mechanisms that mediate ***apoptosis*** have been intensively studied. These
mechanisms involve the activation of endogenous proteases, loss of mitochondrial
function, and structural changes such as disruption. . .

The various signals that trigger ***apoptosis*** are thought to bring about these
events by converging on a common ***cell*** ***death*** pathway, the core components of which
are highly conserved from wonns, such as C. elegans, to humans. In fact, invertebrate
model systems have been invaluable tools in identifying and characterizing the genes
that control ***apoptosis*** . Despite this conservation of certain core components, apoptotic
signaling in mammals is much more complex than in invertebrates. For example, in
4
mammals there are multiple homologues of the core components in the ***cell*** ***death***
signaling pathway.

. . .
to the apoptotic program, are responsible
for the degradation of cellular proteins that leads to the morphological changes seen in
cells undergoing ***apoptosis*** . Caspases (cysteinyl aspartate-specific proteinases) are
cysteine proteases having specificity for aspartate at the substrate cleavage site.

. . .
interaction domains, the death domain, the death effector
domain and the caspase recruitment domain (CARD), have been identified within
proteins involved in ***apoptosis*** . A fourth protein-protein interaction domain, the death
recruiting domain (DRD) was recently identified in murine FLASH (Imai et al. (I 999)
Nature. . .

Caspases comprise a multi-gene family having at least 12 distinct family members (Nicholson (1999) ***Cell*** ***Death*** and
Differentiation 6: 1028). A relatively
small fraction of cellular polypeptides (less than 200) are thought to serve as targets
for cleavage. . . these caspase targets perforin key cellular functions, their proteolysis is thought to account for the cellular and morphological

events that occur during ***apoptosis*** . Members of the caspase gene family can be
divided by phylogenetic analysis into two major subfamilies, based upon their
relatedness to ICE. . .

. . .

SEQ ID NO:2 or
35, in addition to, its encoding nucleic acid, wherein the medical condition is a
disorder related to aberrant ***apoptosis*** modulation, either directly or indirectly.

. . .

and/or fragments thereof, have uses that include detecting, prognosing, treating, preventing, and/or ameliorating the following diseases and/or
disorders, disorders related to aberrant ***apoptosis*** regulation, disorders related to
aberrant cell adhesion regulation, and disorders related to aberrant cellular
proliferation, for example, in addition to, neural, immune,. . .

. . .

Ml-I,146, Ml-RI45, Ml-NI44,
MI-DI43, Ml-F142, Ml-LI41, Ml-E140, MI-LI39, MI-TI38, Ml-NI37, MI-L136,
MI-SI35, MI-PI34, MI-LI33, MI-G132, MI-N131, MI-F130, Ml-A129, Ml-
G128] Ml-VI27, MI-E126, Ml-1125, MI- ***KI24*** , Ml-R123, Ml-VI22, MI-L121,
MI-N12O]Ml-Kll9]MI-Sll8]Ml-LI17]MI-QI16]MI-LI155MI-1114]MI-Ell3]
MI-I,112, Ml-Hlll, Ml-RHO, MI-1,109, MI-HI08, MI-KI07, MI-F106, Ml-50
T105] MI-D104, MIJ103, Ml-R102, Ml-1101, MIN10% Ml-Q99] M1-198] Ml-
G979 Ml-N96, Ml-E953. . .

. . .

anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus
toxoid . For instance, peptides containing cysteine residues may be coupled to a carrier
using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS),. . .

117
Further, an antibody or fragment thereof may be conjugated to a therapeutic
moiety such as a ***cytotoxin*** , e.g., a cytostatic or cytocidal agent, a therapeutic agent or
a radioactive metal ion, e.g., alpha-emitters such as, for example, 21313i. A ***cytotoxin***
or cytotoxic agent includes any agent that is detrimental to cells. Examples include
paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,
etoposide,. . .

. . .

example, the drug moiety may be a protein
or polypeptide possessing a desired biological activity. Such proteins may include, for
example, a ***toxin*** such as abrin, ricin A, pseudomonas exotoxin, or diphtheria ***toxin*** ; a
protein such as tumor necrosis factor, a-interferon, B-interferon, nerve growth factor,
platelet derived growth factor, tissue plasminogen activator, an apoptotic agent,. . .

. . .

Detection And Therapy, Baldwin et
al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., The Preparation And
Cytotoxic Properties Of Antibody- ***Toxin*** Conjugates, Immunol. Rev. 62:119-58
(1982).

. . .

yet to be detennined,
toxins, such as ricin, saporin (Mashiba H, et al., Ann. N. Y. Acad. Sci. 1999;886:233-
5), or HC ***toxin*** (Tonukari NJ, et al., Plant Cell. 2000 Feb;12(2):237-248), for

example. Such fusions could be used to deliver the toxins to desired. . .

. . .
the fusion of antibodies directed against
polypeptides of the present invention, including variants and ftagments thereof, to
said toxins for delivering the ***toxin*** to specific locations in a cell, to specific tissues,
and/or to specific species. Such bifunctional antibodies are known in the art,. . . in addition to the references cited therein, are hereby incorporated by
reference in their entirety herein. In this context, the term ***toxin*** may be expanded to
include any heterologous protein, a small molecule, radionucleotides, cytotoxic drugs,
liposomes, adhesion molecules, glycoproteins, ligands, cell or tissue-specific. . . antibodies,
polyclonal antibodies and genetic material. In view of the present disclosure, one
skilled in the art could determine whether any particular ***toxin*** could be used in the
compounds of the present invention. Examples of suitable toxins listed above are
exemplary only and are not. . .

. . .
protein fusions, of the present invention, or fragments
thereof may be useful in inhibiting proliferative cells or tissues through the induction
of ***apoptosis*** . Said polypeptides may act either directly, or indirectly to induce
apoptosis of proliferative cells and tissues, for example in the activation of a death-
domain receptor, such as tumor necrosis factor (TNF) receptor- 1, CD95 (Fas/APO- 1),
TNF-receptor-related ***apoptosis*** -mediated protein (TRAMP) and TNIT-related
apoptosis -inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et al.,
Ear J Biochem. 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said
polypeptides may induce ***apoptosis*** through other mechanisms, such as in the
activation of other proteins which will activate ***apoptosis*** , or through stimulating the
expression of said proteins, either alone or in combination with small molecule drags
or adjuvants, such as apoptonin,. . .

Diseases at the CeHular Level
Diseases associated with increased cell survival or the inhibition of ***apoptosis***
that could be treated, prevented, and/or diagnosed by the polynucleotides or
polypeptides and/or antagonists or agonists of the invention, include cancers (such. . .

Diseases associated with increased ***apoptosis*** that could be treated, prevented,
and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or
antagonists of the invention, include AIDS; neurodegenerative. . .
by.myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,
hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury)
and liver cancer); ***toxin*** -induced liver disease (such as that caused by alcohol), septic
shock, cachexia and anorexia.

. . .
and/or diagnosed according to the invention include,
but are not limited to, diseases, disorders, and/or conditions such as infarction,
infection, exposure to ***toxin*** , trauma, surgical damage,

degenerative disease or
malignancy that may affect motor neurons as well as other components of the nervous
system, as. . .
. . .
antibodies (or complement fixing
containing portions thereof) that bind an inherent or induced endogenous cytotoxic
effector system, thymidine kinase, endonuclease, RNAse, alpha
toxin , ricin, abrin,
Pseudomonas exotoxin A, diphtheria ***toxin*** , saporin, momordin, gelonin, pokeweed
antiviral protein, alpha-sarcin and cholera ***toxin*** . By cytotoxic prodrug is meant a
non-toxic compound that is converted by an enzyme, normally present in the cell, into
a cytotoxic. . .

Bertin, J., and DiStefano, P. S. (2000). The PYRIN Domain: A novel Motif found in
apoptosis and inflammation proteins. ***Cell***
Death Differ. In press.
. . .
morphogenesis and has striking
similarities to Toll. Development 120, 885
Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. (1992). Identification of
programmed ***cell*** ***death*** in situ via specific labeling of nuclear DNA fragmentation. J.

256
Example 6 - Method Of Assessing The Ability Of HLRRNSI To Modulate ***Apoptosis*** .

The role of the novel HLRRNSI polypeptides in either promoting or inhibiting ***apoptosis*** could be determined by the generation of transfected cell lines
with the HLRRNSI polynucleotides of the present invention, either transient or
stable,. . . by reference in its
entirety) which involves end labeling broken ends of double-stranded DNA with
biotin-conjugated dUTP using terminal transferase. Cells undergoing
cell ***death*** can
then be easily detected by staining with FITC-conjugated streptavidin and flow
cytometric quantitation.
. . .
in the mitotic index where HLRRNS1 stimulates cell
proliferation indicates apoptotic activity. Likewise, a decrease in cell numbers where
HLRRNS I stimulates ***apoptosis*** indicates apoptotic activity.
. . .
the cells and other cellular properties. FCM detects and
quantifies the uptake of fluorescent molecules that diagnose events preceding or
coincident with ***cell*** ***death*** . These events include changes in nuclear DNA content as
measured by staining of DNA with propidium iodide; changes in cell size.
. .
. . .
desired 5' end
using a primer specific to the ligated RNA oligonucleotide and a primer specific to the
known sequence of the ***apoptosis*** related of interest. The resultant product is then
sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant
apoptosis related.
. . .
are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also
known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta),
OPGL, FasL, ***CD27L*** , CD30L, CD40L, 4-IBBL, DcR3, OX40L,

TNF-gamma
301
(International Publication No. WO 96/14328), AIM-I (International Publication No.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-
superfamily. Within this family CD40, ***CD27*** , and CD30 along with their respective
ligands CD 154, ***CD70*** , and CD 153 have been found to regulate a variety of immune
responses. Assays which allow for the detection and/or observation. .
.
. . .
peripheral blood monocytes progressively
lose viability when cultured in absence of serum or other stimuli. Their death results
from internally regulated process (***apoptosis***). Addition to the culture of activating
factors, such as TNF-alpha dramatically improves cell survival and prevents DNA
fragmentation. Propidium iodide (PI) staining is used to measure
apoptosis as follows.

CLMEN. . . method for preventing, treating, or ameliorating a medical condition of claim I 1, wherein the medical condition is disorder related to aberrant
apoptosis modulation, either directly or indirectly.
361

=> dis his

(FILE 'HOME' ENTERED AT 16:25:49 ON 15 FEB 2006)

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
ENTERED AT 16:26:14 ON 15 FEB 2006
L1 1932 S CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70
L2 1360872 S TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"
L3 839 S L1 AND L2
L4 762 DUP REMOVE L3 (77 DUPLICATES REMOVED)
L5 513 S L4 AND PY<=2002
L6 2709 S CALICHEAMICIN OR LLE33288 OR LL-E33288
L7 4 S L5 AND L6

FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006

FILE 'PCTFULL' ENTERED AT 16:34:24 ON 15 FEB 2006

FILE 'STNGUIDE' ENTERED AT 16:34:50 ON 15 FEB 2006
L8 0 S L3 AND CD27
L9 0 S L1

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
ENTERED AT 16:37:02 ON 15 FEB 2006
L10 439 S L5 AND CD27
L11 3 S L5 AND KI24

FILE 'STNGUIDE' ENTERED AT 16:38:26 ON 15 FEB 2006

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
ENTERED AT 16:39:26 ON 15 FEB 2006
L12 2 S L5 AND CD27 AND KI24

=> dis L12 1-2 bib

L12 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002094999 PCTFULL ED 20021210 EW 200248
TIEN POLYNUCLEOTIDE ENCODING A NOVEL TRP CHANNEL FAMILY MEMBER, TRP-PLIK2, AND SPLICE VARIANTS THEREOF
TIFR POLYNUCLEOTIDE CODANT UN NOUVEAU MEMBRE DE LA FAMILLE DES CANAUX TRP, TRP-PLIK2, ET VARIANT D'EPISSAGE DE CE POLYNUCLEOTIDE
IN LEE, Ning, 926 Rhoads Drive, Belle Mead, NJ 08807, US [US, US];
CHEN, Jian, 121 York Drive, Princeton, NJ 08540, US [CN, US];
FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US [US, US];

WU, Shujian, 972 Ithan Lande, Langhorne, PA 19047, US [CN, US];
CHANG, Han, 2 Ann's Court, Princeton Junction, NJ 08550, US [US, US];
LEE, Liana, 8 Petunia Drive Apt. 1J, North Brunswick, NJ 08902, US [US, US];
BLANAR, Michael, 1325 Summerhill Drive, Malvern, PA 19355, US [CA, US];
BOL, David, 1467 Franklin Road, Langhorne, PA 19047, US [US, US]

PA BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US [US, US], for all designates States except US;
LEE, Ning, 926 Rhoads Drive, Belle Mead, NJ 08807, US [US, US], for US only;
CHEN, Jian, 121 York Drive, Princeton, NJ 08540, US [CN, US], for US only;
FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US [US, US], for US only;
WU, Shujian, 972 Ithan Lande, Langhorne, PA 19047, US [CN, US], for US only;
CHANG, Han, 2 Ann's Court, Princeton Junction, NJ 08550, US [US, US], for US only;
LEE, Liana, 8 Petunia Drive Apt. 1J, North Brunswick, NJ 08902, US [US, US], for US only;
BLANAR, Michael, 1325 Summerhill Drive, Malvern, PA 19355, US [CA, US], for US only;
BOL, David, 1467 Franklin Road, Langhorne, PA 19047, US [US, US], for US only

AG D'AMICO, Stephen, Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US

LAF English
LA English
DT Patent
PI ***WO 2002094999 A2 20021128***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-US16164 A 20020522
PRAI US 2001-60/292,599 20010522
US 2002-60/362,944 20020308

L12 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002074959 PCTFULL ED 20021010 EW 200239
TIEN A NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN EXPRESSED PREDOMINATELY IN NERVOUS SYSTEM TISSUES, HLRRNS1
TIFR HLRRNS1: NOUVELLE PROTEINE HUMAINE A REPETITIONS RICHES EN LEUCINE EXPRIMEE ESSENTIELLEMENT DANS DES TISSUS DU SYSTEME NERVEUX
IN RAMANATHAN, Chandra, 41 Alison Avenue, Wallingford, CT 06492, US;
FEDER, John, 277 Dutchtown Zion Road, Belle Mead, NJ 08502, US;
MINTIER, Gabe, 318 Morrison Ave., Hightstown, NJ 08520, US
PA BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US [US, US]
AG D'AMICO, Stephen, Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000, US
LAF English
LA English
DT Patent
PI ***WO 2002074959 A2 20020926***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US50457 A 20011220
PRAI US 2001-60/259,479 20010103
US 2001-60/260,616 20010109

```
=>
=> dis his

     (FILE 'HOME' ENTERED AT 16:25:49 ON 15 FEB 2006)

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:26:14 ON 15 FEB 2006
L1          1932 S CD70 OR CD27L OR CD27LG OR KI24 OR KI-24 OR ANTI-CD70
L2       1360872 S TOXOID OR TOXIN OR CYTOTOXIN OR APOPTOSIS OR "CELL DEATH"
L3           839 S L1 AND L2
L4           762 DUP REMOVE L3 (77 DUPLICATES REMOVED)
L5           513 S L4 AND PY<=2002
L6          2709 S CALICHEAMICIN OR LLE33288 OR LL-E33288
L7             4 S L5 AND L6

     FILE 'STNGUIDE' ENTERED AT 16:31:31 ON 15 FEB 2006

     FILE 'PCTFULL' ENTERED AT 16:34:24 ON 15 FEB 2006

     FILE 'STNGUIDE' ENTERED AT 16:34:50 ON 15 FEB 2006
L8             0 S L3 AND CD27
L9             0 S L1

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:37:02 ON 15 FEB 2006
L10          439 S L5 AND CD27
L11            3 S L5 AND KI24

     FILE 'STNGUIDE' ENTERED AT 16:38:26 ON 15 FEB 2006

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, TOXCENTER, DISSABS, PCTFULL'
     ENTERED AT 16:39:26 ON 15 FEB 2006
L12            2 S L5 AND CD27 AND KI24

=> dis L7 1-4 bib

L7     ANSWER 1 OF 4     PCTFULL   COPYRIGHT 2006 Univentio on STN
AN     2002083921 PCTFULL  ED 20021107  EW 200243
TIEN   NULEIC ACIDS AND CORRESPONDING PROTEINS USEFUL IN THE DETECTION AND
       TREATMENT OF VARIOUS CANCERS
TIFR   ACIDES NUCLEIQUES ET PROTEINES CORRESPONDANTES UTILES POUR LA DETECTION
       ET LE TRAITEMENT DE DIVERS CANCERS
IN     JAKOBOVITS, Aya, 3135 Hutton Drive, Beverly Hills, CA 90210, US;
       CHALLITA-EID, Pia, M., 15745 Morrison Street, Encino, CA 91436, US;
       FARIS, Mary, 2538 Almaden Court, Los Angeles, CA 90077, US;
       GE, Wangmao, Apt. #314, 4838 Hollow Corner Road, Culver City, CA 90230,
       US;
       HUBERT, Rene, S., 1644 No. Occidental Boulevard, Los Angeles, CA 90026,
       US;
       MORRISON, Karen, 1044 Yale Street, Santa Monica, CA 90403, US;
       MORRISON, Robert, Kendall, 1044 Yale Street, Santa Monica, CA 90403, US;
       RAITANO, Arthur, B., 10807 Cushdon Avenue, Los Angeles, CA 90064, US
PA     AGENSYS, INC., 1545 17th Street, Santa Monica, CA 90404, US [US, US]
AG     MURASHIGE, Kate, H., Morrison & Foerster LLP, Suite 500, 3811 Valley
       Centre Drive, San Diego, CA 92130-2332, US
LAF    English
LA     English
DT     Patent
PI       ***WO 2002083921         A2 20021024***
DS     W:             AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
                      CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
                      IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
                      MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
                      TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
       RW (ARIPO):    GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
       RW (EAPO):     AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):      AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
       RW (OAPI):     BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI     WO 2002-US11654       A  20020410
PRAI   US 2001-60/283,112       20010410
       US 2001-60/282,739       20010410
       US 2001-60/286,630       20010425

L7     ANSWER 2 OF 4     PCTFULL   COPYRIGHT 2006 Univentio on STN
AN     2002029032 PCTFULL  ED 20020627  EW 200215
```

TIEN WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TIFR MANIPULATION DE CELLULE ENTIERE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT PAR REPETITION
IN SHORT, Jay, M., P.O. Box 7214, Rancho Santa Fe, CA 92067-7214, US [US, US];
FU, Pengcheng, 7588 Charmant Drive #1914, San Diego, CA 92122-5079, US [AU, US];
LATTERICH, Martin, 12539 Motellano Terrace, San Diego, CA 92130, US [DE, US];
WEI, Jing, 10725 Wexford St. #6, San Diego, CA 92131, US [CN, US];
LEVIN, Michael, 7565 Tupelo Cove, San Diego, CA 92126, US [RU, US]
PA DIVERSA CORPORATION, 4955 Directors Place, San Diego, CA 92121, US [US, US], for all designates States except US;
SHORT, Jay, M., P.O. Box 7214, Rancho Santa Fe, CA 92067-7214, US [US, US], for US only;
FU, Pengcheng, 7588 Charmant Drive #1914, San Diego, CA 92122-5079, US [AU, US], for US only;
LATTERICH, Martin, 12539 Motellano Terrace, San Diego, CA 92130, US [DE, US], for US only;
WEI, Jing, 10725 Wexford St. #6, San Diego, CA 92131, US [CN, US], for US only;
LEVIN, Michael, 7565 Tupelo Cove, San Diego, CA 92126, US [RU, US], for US only
AG EINHORN, Gregory, P., Fish & Richardson P.C., 4350 La Jolla Village Drive, San Diego, CA 92122, US
LAF English
LA English
DT Patent
PI ***WO 2002029032 A2 20020411***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US31004 A 20011001
PRAI US 2000-09/677,584 20000930
US 2001-60/279,702 20010328
US 2001-PCT/US01/19367 20010614

L7 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002018620 PCTFULL ED 20020705 EW 200210
TIEN NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
TIFR NEUTROKINE-ALPHA ET VARIANT D'EPISSAGE DE NEUTROKINE-ALPHA
IN YU, Guo-Liang, 242 Gravatt Drive, Berkeley, CA 94705, US [US, US];
EBNER, Reinhard, 9906 Shelburne Terrace #316, Gaithersburg, MD 20878, US [DE, US];
NI, Jian, 17815 Fair Lady Way, Germantown, MD 20874, US [CN, US];
ROSEN, Craig, A., 22400 Rolling Hill Lane, Laytonsville, MD 20882, US [US, US];
ULLRICH, Stephen, 4713 Rams Head Court, Rockville, MD 20853, US [US, US]
PA HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue, Rockville, MD 20850, US [US, US], for all designates States except US;
YU, Guo-Liang, 242 Gravatt Drive, Berkeley, CA 94705, US [US, US], for US only;
EBNER, Reinhard, 9906 Shelburne Terrace #316, Gaithersburg, MD 20878, US [DE, US], for US only;
NI, Jian, 17815 Fair Lady Way, Germantown, MD 20874, US [CN, US], for US only;
ROSEN, Craig, A., 22400 Rolling Hill Lane, Laytonsville, MD 20882, US [US, US], for US only;
ULLRICH, Stephen, 4713 Rams Head Court, Rockville, MD 20853, US [US, US], for US only
AG HOOVER, Kenley, 9410 Key West Avenue, Rockville, MD 20850, US
LAF English
LA English
DT Patent
PI ***WO 2002018620 A2 20020307***
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS

```
                    JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
                    MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
                    UA UG US UZ VN YU ZA ZW
        RW (ARIPO):    GH GM KE LS MW MZ SD SL SZ TZ UG ZW
        RW (EAPO):     AM AZ BY KG KZ MD RU TJ TM
        RW (EPO):      AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
        RW (OAPI):     BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI      WO 2001-US25549       A  20010815
PRAI    US 2000-60/225,628       20000815
        US 2000-60/227,008       20000823
        US 2000-60/234,338       20000922
        US 2000-60/240,806       20001017
        US 2000-60/250,020       20001130
        US 2001-60/276,248       20010306
        US 2001-60/293,499       20010525
        US 2001-60/296,122       20010607
        US 2001-60/304,809       20010713

L7      ANSWER 4 OF 4      PCTFULL   COPYRIGHT 2006 Univentio on STN
AN      2001096551 PCTFULL  ED 20020826
TIEN    WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A
        STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TIFR    INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE
        D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT
        REPETITION
IN      SHORT, Jay, M.
PA      DIVERSA CORPORATION;
        SHORT, Jay, M.
DT      Patent
PI        ***WO 2001096551         A2 20011220***
DS      W:             AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
                       CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
                       IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
                       MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
                       TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ
                       UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
                       FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN
                       GW ML MR NE SN TD TG
AI      WO 2001-US19367       A  20010614
PRAI    US 2000-09/594,459       20000614
        US 2000-09/677,584       20000930


=> log y
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     63.28     125.74

STN INTERNATIONAL LOGOFF AT 17:06:13 ON 15 FEB 2006
```